Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 25:7:F1000 Faculty Rev-1136.
doi: 10.12688/f1000research.14122.1. eCollection 2018.

Current overview and treatment of mantle cell lymphoma

Michael Schieber  1 , Leo I Gordon  1 , Reem Karmali  1
Affiliations
Review

Current overview and treatment of mantle cell lymphoma

Michael Schieber et al. F1000Res. .

Abstract

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with historically poor long-term survival compared with other B-cell malignancies. Treatment strategies for this disease are variable and dependent on symptoms and patient fitness. Despite recent advances, MCL remains incurable and patients with high-risk disease have particularly poor outcomes. This review focuses on recent developments that enhance our understanding of the biology of MCL and new treatment approaches that have led to substantial improvements in clinical outcomes. We will outline induction immuno-chemotherapy and maintenance strategies in transplant-eligible patients. In addition, effective strategies for patients unfit for intensive induction will be discussed, with a particular focus on novel molecular therapies with activity in MCL. Lastly, a number of ongoing clinical trials will be presented; the data from these trials are anticipated to redefine standards of care in the near future.

Keywords: Clinical trials; Diagnosis; Management; Mantle Cell Lymphoma; Treatment.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Salaverria I, Royo C, Carvajal-Cuenca A, et al. : CCND2 rearrangements are the most frequent genetic events in cyclin D1 - mantle cell lymphoma. Blood. 2013;121(8):1394–402. 10.1182/blood-2012-08-452284 - DOI - PMC - PubMed
    1. Mozos A, Royo C, Hartmann E, et al. : SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555–62. 10.3324/haematol.2009.010264 - DOI - PMC - PubMed
    1. Vegliante MC, Palomero J, Pérez-Galán P, et al. : SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121(12):2175–85. 10.1182/blood-2012-06-438937 - DOI - PubMed
    1. Navarro A, Clot G, Royo C, et al. : Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72(20):5307–16. 10.1158/0008-5472.CAN-12-1615 - DOI - PMC - PubMed
    1. Abrisqueta P, Scott DW, Slack GW, et al. : Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017;28(10):2489–95. 10.1093/annonc/mdx333 - DOI - PubMed

    2. F1000 Recommendation

LinkOut - more resources